Inventor · disambiguated record
Xi-Tao Wang
Also filed as: Wang xi-tao
21 granted patents·6 pending applications·652 citations·filing 2013–2024
97Inventor score
Files withBRISTOL MYERS SQUIBB CO27
Top patents by PatentIndex Score
27 records- 0198US10604575B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 31, 2020·26 cites·17 claims
- 0298US10323092B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·30 cites·26 claims
- 0398US10323093B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·29 cites·18 claims
- 0498US10316091B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·30 cites·26 claims
- 0598US10308714B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 4, 2019·30 cites·27 claims
- 0698US10266595B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·28 cites·30 claims
- 0798US10266594B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 0898US10266596B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 0998US10138299B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 27, 2018·39 cites·25 claims
- 1098US10072082B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 11, 2018·58 cites·28 claims
- 1198US9856320B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 2, 2018·94 cites·22 claims
- 1297US10584170B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 10, 2020·23 cites·27 claims
- 1397US10577423B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 3, 2020·23 cites·27 claims
- 1497US10316090B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·29 cites·27 claims
- 1597US9212224B2Antibodies that bind PD-L1 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Dec 15, 2015·135 cites·2 claims
- 1695US9644032B2Antibodies against OX40 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted May 9, 2017·12 cites·30 claims
- 1792US10690674B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 23, 2020·5 cites·27 claims
- 1892US2024417471A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1986US2024002512A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2086US2024034793A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2184US11408889B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 2283US11466092B2Antibodies against OX-40 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Oct 11, 2022·1 cites·19 claims
- 2381US10683357B2Antibodies against OX40 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jun 16, 2020·1 cites·19 claims
- 2478US2023272100A1Antibodies against ox-40 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2575US2020308282A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2652US12139551B2Anti-IDO antibody and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 12, 2024·0 cites·35 claims
- 2749US2023119066A1Anti-ccr8 antibodies for treating cancerBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xi-Tao Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →